Error Management Training
The Mass is Back
>
Error is inevitable; harm is not.
>
Train to catch and learn from errors early.
>
You will analyse 1 real case to test your judgment under
pressure.
A real clinical scenario.
Can you make the right decision
under pressure?
First case
You’re presented with the following case:
Patient:
Margins reported as narrow but free of tumour cells.
7-year-old neutered male Golden Retriever
History
Current complaint
Solitary 2 cm cutaneous mast cell tumour on right lateral flank. FNA consistent with a mast cell tumour. Mass was surgically excised by the primary veterinarian.
3 months after surgery, the owner reports a new lump at the previous surgical site
Histopathology (post-excision) Cutaneous mast cell tumour Intermediate grade (Patnaik system)
Next
Physical examination findings
Firm subcutaneous mass at the original excision siteNo overt systemic signs No documented lymph node assessment at the original surgery
Cytology
Fine needle aspiration confirms recurrent mast cell tumour
Next
Owner says
"I thought it was all removed last time."
"He seems fine otherwise, can’t we just take it off again like before?"
Next
Before you continue…
You are about to review several clinical
statements. Please assess each one
independently using the decision scale below.
In this activity, you take the role of a second clinician: reviewing the decision made, weighing its potential consequences, and reflecting on how it might have been approached differently.
Tap or hover on each icon to see what every category means.
Make your clinical decision
Proceed with simple re-excision of the recurrent mass without additional staging or reassessment.
It would be acceptable if...
Critical Error
Could proceeding directly to surgery cause harm (clinical, diagnostic, or prognostic), and under what circumstances, if any, might this still be defensible?
Before selecting your answer, justify your choice by comparing the communication style, reasoning quality, alignment with the readings, and key differences between both responses.
Next
Recurrence suggests either incomplete microscopic excision, aggressive tumour biology, or both.
Re-excising without reassessment ignores recurrence prognostic significance and risks inadequate oncologic control.
Critical Error
Conditionally reasonable, but only with careful reassessment and informed owner consent.
Reasonable– if justified after owner discussion
It would be acceptable if...
Next
“Undertake full restaging including regional lymph node aspiration and abdominal ultrasound before definitive management.”
Appropriate
It would be acceptable if...
What diagnostic, prognostic, and communicative benefits does restaging provide, and how would you justify this to the owner?
Before selecting your answer, justify your choice by comparing the communication style, reasoning quality, alignment with the readings, and key differences between both responses.
Next
Limiting diagnostics may appear cost-effective but risks false reassurance and missed metastatic disease.
It would be acceptable if...
Restaging aligns with best practice for recurrent mast cell tumours.
Appropriate
Next
Repeat excision may be appropriate, but only after: – Re-evaluation of tumour grade (preferably using a 2-tier system) – Assessment of surgical margins from the original excision – Consideration of lymph node aspiration and abdominal staging Proceeding blindly risks repeating the same error that led to recurrence. Evidence demonstrates that tumour biology and margin quality,not just surgical intent, determine outcome
Ask Yourself
Because the mass has returned, we need to reassess how aggressive it may be and whether it has spread before deciding on the best treatment together.
This approach may be defensible only when tumour biology is clearly low risk and recurrence is confidently attributable to technical margin failure, which are conditions not met in this case.
Mast cell tumours demonstrate tropism for lymph nodes, spleen, liver, and gastrointestinal tract, and metastasis may occur despite unremarkable physical findings. Lymph node palpation alone is insufficient, as nodes may harbour metastasis while appearing normal. Abdominal ultrasound with aspirates is justified in recurrent or higher-risk cases
Mast cell tumours demonstrate unpredictable behaviour, and recurrence is a recognised negative prognostic indicator. Failure to reassess risks: 1) Underestimating tumour grade or progression. 2) Missing nodal or visceral metastasis. 3) Repeating inadequate margins. 4) Reducing future local control and survival. This contradicts established principles of surgical oncology and mast cell tumour management, which emphasise staging, grading, and margin planning before intervention.
Ask Yourself
Have I fully reassessed this recurrent mast cell tumour (grade, stage, metastasis) before re-intervening? Will my planned surgery achieve appropriate margins and improve prognosis based on current tumour biology?
SAST_M3_EMT_The Mass is Back
Improve International
Created on December 31, 2025
Start designing with a free template
Discover more than 1500 professional designs like these:
View
Teaching Challenge: Transform Your Classroom
View
Branching Scenario Mission: Innovating for the Future
View
Branching Scenarios Challenge Mobile
View
Branching Scenario: Academic Ethics and AI Use
View
Branching Scenario: College Life
View
Strategic Decisions: Branching Scenario
View
Branching Scenarios Challenge
Explore all templates
Transcript
Error Management Training
The Mass is Back
>
Error is inevitable; harm is not.
>
Train to catch and learn from errors early.
>
You will analyse 1 real case to test your judgment under pressure.
A real clinical scenario.
Can you make the right decision under pressure?
First case
You’re presented with the following case:
Patient:
Margins reported as narrow but free of tumour cells.
7-year-old neutered male Golden Retriever
History
Current complaint
Solitary 2 cm cutaneous mast cell tumour on right lateral flank. FNA consistent with a mast cell tumour. Mass was surgically excised by the primary veterinarian.
3 months after surgery, the owner reports a new lump at the previous surgical site
Histopathology (post-excision) Cutaneous mast cell tumour Intermediate grade (Patnaik system)
Next
Physical examination findings
Firm subcutaneous mass at the original excision siteNo overt systemic signs No documented lymph node assessment at the original surgery
Cytology
Fine needle aspiration confirms recurrent mast cell tumour
Next
Owner says
"I thought it was all removed last time."
"He seems fine otherwise, can’t we just take it off again like before?"
Next
Before you continue…
You are about to review several clinical statements. Please assess each one independently using the decision scale below.
In this activity, you take the role of a second clinician: reviewing the decision made, weighing its potential consequences, and reflecting on how it might have been approached differently.
Tap or hover on each icon to see what every category means.
Make your clinical decision
Proceed with simple re-excision of the recurrent mass without additional staging or reassessment.
It would be acceptable if...
Critical Error
Could proceeding directly to surgery cause harm (clinical, diagnostic, or prognostic), and under what circumstances, if any, might this still be defensible?
Before selecting your answer, justify your choice by comparing the communication style, reasoning quality, alignment with the readings, and key differences between both responses.
Next
Recurrence suggests either incomplete microscopic excision, aggressive tumour biology, or both.
Re-excising without reassessment ignores recurrence prognostic significance and risks inadequate oncologic control.
Critical Error
Conditionally reasonable, but only with careful reassessment and informed owner consent.
Reasonable– if justified after owner discussion
It would be acceptable if...
Next
“Undertake full restaging including regional lymph node aspiration and abdominal ultrasound before definitive management.”
Appropriate
It would be acceptable if...
What diagnostic, prognostic, and communicative benefits does restaging provide, and how would you justify this to the owner?
Before selecting your answer, justify your choice by comparing the communication style, reasoning quality, alignment with the readings, and key differences between both responses.
Next
Limiting diagnostics may appear cost-effective but risks false reassurance and missed metastatic disease.
It would be acceptable if...
Restaging aligns with best practice for recurrent mast cell tumours.
Appropriate
Next
Repeat excision may be appropriate, but only after: – Re-evaluation of tumour grade (preferably using a 2-tier system) – Assessment of surgical margins from the original excision – Consideration of lymph node aspiration and abdominal staging Proceeding blindly risks repeating the same error that led to recurrence. Evidence demonstrates that tumour biology and margin quality,not just surgical intent, determine outcome
Ask Yourself
Because the mass has returned, we need to reassess how aggressive it may be and whether it has spread before deciding on the best treatment together.
This approach may be defensible only when tumour biology is clearly low risk and recurrence is confidently attributable to technical margin failure, which are conditions not met in this case.
Mast cell tumours demonstrate tropism for lymph nodes, spleen, liver, and gastrointestinal tract, and metastasis may occur despite unremarkable physical findings. Lymph node palpation alone is insufficient, as nodes may harbour metastasis while appearing normal. Abdominal ultrasound with aspirates is justified in recurrent or higher-risk cases
Mast cell tumours demonstrate unpredictable behaviour, and recurrence is a recognised negative prognostic indicator. Failure to reassess risks: 1) Underestimating tumour grade or progression. 2) Missing nodal or visceral metastasis. 3) Repeating inadequate margins. 4) Reducing future local control and survival. This contradicts established principles of surgical oncology and mast cell tumour management, which emphasise staging, grading, and margin planning before intervention.
Ask Yourself
Have I fully reassessed this recurrent mast cell tumour (grade, stage, metastasis) before re-intervening? Will my planned surgery achieve appropriate margins and improve prognosis based on current tumour biology?